Retraction: EGFR inhibition in glioma cells modulates rho signaling to inhibit cell motility and invasion and cooperates with temozolomide to reduce cell growth (PLoS ONE (2012) 7: 6 (e38770) DOI: 10.1371/journal.pone.0038770);EGFR inhibition in glioma cells modulates rho signaling to inhibit cell motility and invasion and cooperates with temozolomide to reduce cell growth

PLoS ONE

Volumn 7, Issue 6, 2012, Pages

  Ramis, Guillem ^a   Thomàs Moyà, Elena ^a   de Mattos, Silvia ^a   Rodríguez, José ^a,b   Villalonga, Priam ^a  

^a UNIVERSITAT DE LES ILLES BALEARS   (Spain)

^b HOSPITAL SEVERO OCHOA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIN; CYCLIN D1; CYCLIN DEPENDENT KINASE INHIBITOR 1B; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; MITOGEN ACTIVATED PROTEIN KINASE; MUTANT PROTEIN; PROTEIN KINASE B; RETINOBLASTOMA PROTEIN; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; TEMOZOLOMIDE; DACARBAZINE; DRUG DERIVATIVE;

APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL ASSAY; CELL GROWTH; CELL INVASION; CELL MOTILITY; CELL PROLIFERATION; CELL STRUCTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG POTENTIATION; ENZYME INHIBITION; FLOW CYTOMETRY; G1 PHASE CELL CYCLE CHECKPOINT; GLIOMA CELL; HUMAN; HUMAN CELL; MULTICELLULAR SPHEROID; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; RECEPTOR BLOCKING; SIGNAL TRANSDUCTION; STRESS FIBER; CELL MOTION; CLONOGENIC ASSAY; COMPARATIVE STUDY; DRUG EFFECT; GLIOMA; IMMUNOBLOTTING; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; POLYACRYLAMIDE GEL ELECTROPHORESIS;

CELL MOVEMENT; CELL PROLIFERATION; COLONY-FORMING UNITS ASSAY; DACARBAZINE; ELECTROPHORESIS, POLYACRYLAMIDE GEL; FLOW CYTOMETRY; GLIOMA; HUMANS; IMMUNOBLOTTING; RECEPTOR, EPIDERMAL GROWTH FACTOR; RHO GTP-BINDING PROTEINS; SIGNAL TRANSDUCTION;

EID: 84862001878     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0222210     Document Type: Erratum

References (41)

1. Maher EA, Furnari FB, Bachoo RM, Rowitch DH, Louis DN, (2001) Malignant glioma: genetics and biology of a grave matter. Genes Dev 15: 1311 1333.
2. Halatsch ME, Schmidt U, Behnke-Mursch J, Unterberg A, Wirtz CR, (2006) Epidermal growth factor receptor inhibition for the treatment of glioblastoma multiforme and other malignant brain tumours. Cancer Treat Rev 32: 74 89.
3. Nishikawa R, Ji XD, Harmon RC, Lazar CS, Gill GN, (1994) A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. Proc Natl Acad Sci U S A 91: 7727 7731.
4. Huang HS, Nagane M, Klingbeil CK, Lin H, Nishikawa R, (1997) The enhanced tumorigenic activity of a mutant epidermal growth factor receptor common in human cancers is mediated by threshold levels of constitutive tyrosine phosphorylation and unattenuated signaling. J Biol Chem 272: 2927 2935.
5. Halatsch ME, Gehrke EE, Vougioukas VI, Botefur IC, F AB, (2004) Inverse correlation of epidermal growth factor receptor messenger RNA induction and suppression of anchorage-independent growth by OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in glioblastoma multiforme cell lines. J Neurosurg 100: 523 533.
6. Mellinghoff IK, Wang MY, Vivanco I, Haas-Kogan DA, Zhu S, (2005) Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med 353: 2012 2024.
7. Carrasco-Garcia E, Saceda M, Grasso S, Rocamora-Reverte L, Conde M, (2011) Small tyrosine kinase inhibitors interrupt EGFR signaling by interacting with erbB3 and erbB4 in glioblastoma cell lines. Exp Cell Res 317: 1476 1489.
8. Brandes AA, Franceschi E, Tosoni A, Hegi ME, Stupp R, (2008) Epidermal growth factor receptor inhibitors in neuro-oncology: hopes and disappointments. Clin Cancer Res 14: 957 960.
9. Haas-Kogan DA, Prados MD, Tihan T, Eberhard DA, Jelluma N, (2005) Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib. J Natl Cancer Inst 97: 880 887.
10. Wang MY, Lu KV, Zhu S, Dia EQ, Vivanco I, (2006) Mammalian target of rapamycin inhibition promotes response to epidermal growth factor receptor kinase inhibitors in PTEN-deficient and PTEN-intact glioblastoma cells. Cancer Res 66: 7864 7869.
11. Fan QW, Cheng CK, Nicolaides TP, Hackett CS, Knight ZA, (2007) A dual phosphoinositide-3-kinase alpha/mTOR inhibitor cooperates with blockade of epidermal growth factor receptor in PTEN-mutant glioma. Cancer Res 67: 7960 7965.
12. Ren XD, Schwartz MA, (2000) Determination of GTP loading on Rho. Methods Enzymol 325: 264 272.
13. Bradford MM, (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248 254.
14. Kolchinsky A, Roninson IB, (1997) Drug resistance conferred by MDR1 expression in spheroids formed by glioblastoma cell lines. Anticancer Res 17: 3321 3327.
15. Ridley AJ, (2001) Rho family proteins: coordinating cell responses. Trends Cell Biol 11: 471 477.
16. Ridley AJ, (2001) Rho GTPases and cell migration. J Cell Sci 114: 2713 2722.
17. Thomas C, Ely G, James CD, Jenkins R, Kastan M, (2001) Glioblastoma-related gene mutations and over-expression of functional epidermal growth factor receptors in SKMG-3 glioma cells. Acta Neuropathol 101: 605 615.
18. Krakstad C, Chekenya M, (2010) Survival signalling and apoptosis resistance in glioblastomas: opportunities for targeted therapeutics. Mol Cancer 9: 135.
19. Gomez-Manzano C, Lemoine MG, Hu M, He J, Mitlianga P, (2001) Adenovirally-mediated transfer of E2F-1 potentiates chemosensitivity of human glioma cells to temozolomide and BCNU. Int J Oncol 19: 359 365.
20. Brown PD, Krishnan S, Sarkaria JN, Wu W, Jaeckle KA, (2008) Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177. J Clin Oncol 26: 5603 5609.
21. Prados MD, Chang SM, Butowski N, DeBoer R, Parvataneni R, (2009) Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma. J Clin Oncol 27: 579 584.
22. Cheng H, An SJ, Zhang XC, Dong S, Zhang YF, (2011) In vitro sequence-dependent synergism between paclitaxel and gefitinib in human lung cancer cell lines. Cancer Chemother Pharmacol 67: 637 646.
23. Pan F, Tian J, Zhang X, Zhang Y, Pan Y, (2011) Synergistic interaction between sunitinib and docetaxel is sequence dependent in human non-small lung cancer with EGFR TKIs-resistant mutation. J Cancer Res Clin Oncol 137: 1397 1408.
24. Pawlik TM, Keyomarsi K, (2004) Role of cell cycle in mediating sensitivity to radiotherapy. Int J Radiat Oncol Biol Phys 59: 928 942.
25. Haas-Kogan DA, Prados MD, Lamborn KR, Tihan T, Berger MS, (2005) Biomarkers to predict response to epidermal growth factor receptor inhibitors. Cell Cycle 4: 1369 1372.
26. Fan QW, Specht KM, Zhang C, Goldenberg DD, Shokat KM, (2003) Combinatorial efficacy achieved through two-point blockade within a signaling pathway-a chemical genetic approach. Cancer Res 63: 8930 8938.
27. Stommel JM, Kimmelman AC, Ying H, Nabioullin R, Ponugoti AH, (2007) Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science 318: 287 290.
28. Griffero F, Daga A, Marubbi D, Capra MC, Melotti A, (2009) Different response of human glioma tumor-initiating cells to EGFR kinase inhibitors. J Biol Chem.
29. Weber JD, Raben DM, Phillips PJ, Baldassare JJ, (1997) Sustained activation of extracellular-signal-regulated kinase 1 (ERK1) is required for the continued expression of cyclin D1 in G1 phase. Biochem J 326 (Pt 1): 61-68.
30. Takuwa N, Fukui Y, Takuwa Y, (1999) Cyclin D1 expression mediated by phosphatidylinositol 3-kinase through mTOR-p70(S6K)-independent signaling in growth factor-stimulated NIH 3T3 fibroblasts. Mol Cell Biol 19: 1346 1358.
31. Amanatullah DF, Zafonte BT, Albanese C, Fu M, Messiers C, (2001) Ras regulation of cyclin D1 promoter. Methods Enzymol 333: 116 127.
32. Medema RH, Kops GJ, Bos JL, Burgering BM, (2000) AFX-like Forkhead transcription factors mediate cell-cycle regulation by Ras and PKB through p27kip1. Nature 404: 782 787.
33. Ridley AJ, Hall A, (1992) The small GTP-binding protein rho regulates the assembly of focal adhesions and actin stress fibers in response to growth factors. Cell 70: 389 399.
34. Sander EE, ten Klooster JP, van Delft S, van der Kammen RA, Collard JG, (1999) Rac downregulates Rho activity: reciprocal balance between both GTPases determines cellular morphology and migratory behavior. J Cell Biol 147: 1009 1022.
35. Goldberg L, Kloog Y, (2006) A Ras inhibitor tilts the balance between Rac and Rho and blocks phosphatidylinositol 3-kinase-dependent glioblastoma cell migration. Cancer Res 66: 11709 11717.
36. Halatsch ME, Low S, Mursch K, Hielscher T, Schmidt U, (2009) Candidate genes for sensitivity and resistance of human glioblastoma multiforme cell lines to erlotinib. Laboratory investigation. J Neurosurg 111: 211 218.
37. Riganti C, Aldieri E, Doublier S, Bosia A, Ghigo D, (2008) Statins-mediated inhibition of rho GTPases as a potential tool in anti-tumor therapy. Mini Rev Med Chem 8: 609 618.
38. Cemeus C, Zhao TT, Barrett GM, Lorimer IA, Dimitroulakos J, (2008) Lovastatin enhances gefitinib activity in glioblastoma cells irrespective of EGFRvIII and PTEN status. J Neurooncol 90: 9 17.
39. Giese A, Bjerkvig R, Berens ME, Westphal M, (2003) Cost of migration: invasion of malignant gliomas and implications for treatment. J Clin Oncol 21: 1624 1636.
40. Wild-Bode C, Weller M, Rimner A, Dichgans J, Wick W, (2001) Sublethal irradiation promotes migration and invasiveness of glioma cells: implications for radiotherapy of human glioblastoma. Cancer Res 61: 2744 2750.
41. Zhai GG, Malhotra R, Delaney M, Latham D, Nestler U, (2006) Radiation enhances the invasive potential of primary glioblastoma cells via activation of the Rho signaling pathway. J Neurooncol 76: 227 237.